Hillsdale Investment Management Inc. Buys New Position in Enanta Pharmaceuticals, Inc. $ENTA

Hillsdale Investment Management Inc. bought a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 422,300 shares of the biotechnology company’s stock, valued at approximately $6,660,000. Hillsdale Investment Management Inc. owned approximately 1.46% of Enanta Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ENTA. AQR Capital Management LLC raised its stake in Enanta Pharmaceuticals by 674.7% in the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after purchasing an additional 311,010 shares in the last quarter. Millennium Management LLC raised its stake in Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after purchasing an additional 449,945 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Enanta Pharmaceuticals by 5.3% in the first quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 6,549 shares in the last quarter. Invesco Ltd. raised its stake in shares of Enanta Pharmaceuticals by 4.3% during the second quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock worth $475,000 after acquiring an additional 2,607 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Enanta Pharmaceuticals by 0.8% during the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after acquiring an additional 6,522 shares in the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ENTA has been the subject of a number of recent research reports. Rodman & Renshaw initiated coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Monday, April 20th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $13.16 on Friday. The firm has a market cap of $382.69 million, a price-to-earnings ratio of -5.08 and a beta of 1.01. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $5.87 and a fifty-two week high of $17.15. The firm has a 50 day moving average price of $13.61 and a 200-day moving average price of $13.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.01. The company had revenue of $17.16 million for the quarter, compared to the consensus estimate of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. As a group, equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.